The YEL023C gene encodes a hypothetical protein with no annotated enzymatic or structural domains. Antibodies against YEL023C are typically generated for:
Localization studies: Tracking protein expression during yeast cell cycles or stress responses.
Interaction mapping: Identifying binding partners via co-immunoprecipitation (Co-IP) or yeast two-hybrid screens .
Knockout validation: Confirming gene deletion in mutant strains using Western Blot (WB) .
Commercial and custom YEL023C antibodies are typically monoclonal or polyclonal IgG isoforms. Key validation steps include:
| Assay Type | Purpose | Typical Results for YEL023C Antibody |
|---|---|---|
| Western Blot | Confirm target size (~kDa) | Single band at predicted molecular weight |
| Immunofluorescence | Subcellular localization | Cytoplasmic/nuclear signal in wild-type |
| ELISA | Quantify antigen-antibody affinity | High specificity (EC₅₀ < 10 nM) |
| KO Validation | Specificity in knockout strains | No signal in ΔYEL023C mutants |
Data adapted from antibody characterization pipelines .
YEL023C antibodies are employed in:
Meiotic recombination studies: Genetic markers near YEL023C (e.g., kanMX6 and hygMX6) are used to monitor crossover events in yeast sporulation .
Protein interaction networks: Immunoprecipitation-mass spectrometry (IP-MS) to identify co-purifying proteins .
Functional genomics: Linking YEL023C deletion phenotypes (e.g., growth defects) to broader metabolic pathways .
Low target characterization: The absence of annotated domains complicates functional studies .
Cross-reactivity risks: Antibodies may bind off-target proteins in yeast lysates without rigorous validation .
Commercial availability: Few vendors supply YEL023C antibodies, necessitating custom generation .
While direct studies on YEL023C are sparse, related work highlights:
Epitope conservation: Antibodies against uncharacterized yeast proteins often recognize linear epitopes in variable regions .
Utility in synthetic lethality screens: Antibodies help identify genetic interactions in high-throughput assays .
YEL023C is the systematic name for the NBP2 gene in Saccharomyces cerevisiae (budding yeast). This gene encodes Nbp2p, a protein that functions primarily as an adaptor molecule in multiple cellular pathways. Nbp2p has been shown to participate in protein-protein interaction networks, particularly as a mediator between phosphatase Ptc1p and other signaling proteins. The systematic naming follows yeast genome convention where YEL indicates chromosome V (E), left arm (L), and 023C denotes the specific open reading frame on the Crick strand .
Nbp2p contains three distinct functional regions that contribute to its role as an adaptor protein. According to structural analyses, Nbp2p features an N-terminal Ptc1p binding region, followed by a central SH3 (Src Homology 3) domain, and a C-terminal region of undefined function. The N-terminal region (colored grey in analytical diagrams) is specifically involved in binding the phosphatase Ptc1p, while the SH3 domain (colored black in diagrams) mediates interactions with proline-rich sequences in partner proteins .
Nbp2p serves as a critical bridging molecule in multiple signaling pathways by facilitating protein complex formation. Experimental evidence demonstrates that Nbp2p mediates the interaction between the phosphatase Ptc1p and proteins like Bck1p, as deletion of NBP2 results in loss of detectable interaction between these proteins. Split-Ub interaction assays have shown that Nbp2p interacts directly with numerous signaling proteins, suggesting its role in coordinating phosphatase activity with specific signaling events. This adaptor function explains why deletion of NBP2 can result in multiple apparently unconnected phenotypes .
For successful generation of antibodies against the YEL023C-encoded protein (Nbp2p), researchers should consider both monoclonal and polyclonal approaches, each with distinct advantages. Polyclonal antibodies can be produced in approximately 5 weeks using rabbits immunized with either synthetic peptides or purified protein domains from Nbp2p. For optimal results, researchers should:
Select immunogenic epitopes, particularly from the distinctive N-terminal region or SH3 domain
Use KLH-conjugated peptides (minimum 90% purity) for immunization
Perform test bleeds and titer tests before final collection
Purify antibodies using protein A/G chromatography
This approach typically yields approximately 10 mg of purified antibody per production cycle .
Validation of YEL023C antibodies requires multiple complementary approaches to ensure specificity:
Western blot analysis using wild-type yeast extracts alongside Δnbp2 deletion strains to confirm absence of signal in knockout samples
Immunoprecipitation followed by mass spectrometry to identify pulled-down proteins
Immunofluorescence microscopy comparing labeled patterns in wild-type versus deletion strains
Cross-reactivity testing against other SH3 domain-containing proteins to ensure specificity
These validation steps are critical as demonstrated in immunoblotting experiments where non-specific binding can occur, as observed in the analysis of Nbp2p interactions where arrowheads indicated unspecific binding of antibodies in control experiments .
When designing antibodies against YEL023C-encoded Nbp2p, epitope selection should be guided by both structural features and sequence conservation:
Target unique sequences within the N-terminal Ptc1p binding region for antibodies specific to binding interfaces
Select sequences from the SH3 domain that are distinctive from other yeast SH3-containing proteins
Avoid highly conserved regions if species specificity is required
Consider using multiple epitopes from different regions to generate complementary antibodies
Research has shown that epitope selection can significantly impact antibody functionality in recognition of native protein conformations versus denatured forms in techniques like western blotting versus immunoprecipitation .
Multiple complementary techniques have proven effective for studying Nbp2p interactions:
Split-Ub interaction assays: This technique allows detection of in vivo protein interactions by measuring the reconstitution of ubiquitin when fusion proteins interact. Experiments with Nbp2CRU (C-terminal ubiquitin fragment fused to Nbp2p) and various Nub fusion proteins have successfully mapped interaction networks .
GST pull-down assays: GST-Nbp2p loaded onto Sepharose beads effectively pulls down interacting partners from yeast extracts, which can then be detected via immunoblotting. This approach has been used to confirm direct binding between Nbp2p and proteins like Bem4p .
Co-immunoprecipitation: Using antibodies against Nbp2p or epitope-tagged versions to pull down protein complexes from yeast extracts under native conditions.
Yeast two-hybrid screening: Complementary to other approaches for identifying novel interaction partners.
Each method offers different strengths, and combining approaches provides more comprehensive understanding of interaction networks .
When designing experiments to examine Nbp2p-mediated protein complexes, consider the following approach:
Initial mapping experiments: Use Split-Ub assays to identify potential interacting partners, as demonstrated in the interaction assays between Nbp2CRU and selected Nub fusion proteins
Validation studies: Confirm direct interactions through in vitro binding assays using purified components, such as GST-Nbp2p pull-downs
Domain mapping: Create truncated or mutated versions of Nbp2p to determine which domains mediate specific interactions (N-terminal region, SH3 domain, or C-terminal region)
Functional analysis: Test the impact of NBP2 deletion on interactions between partner proteins, as shown in the experiments demonstrating that Ptc1p-Bck1p interaction is lost in Δnbp2 strains
Reciprocal approaches: Examine interactions from multiple perspectives by alternating which protein is used as bait
This multi-faceted approach helps avoid false positives and negatives, as some interactions may not be detected in certain configurations, as noted with Nbp2p-Ste20p and Nbp2p-Cla4p interactions .
When using YEL023C antibodies, the following control experiments are essential:
| Control Type | Implementation | Purpose |
|---|---|---|
| Specificity Controls | Use Δnbp2 deletion strains | Verifies absence of signal in knockout background |
| Loading Controls | Probe for stable reference proteins | Ensures equal loading across samples |
| Expression Controls | Check target protein expression levels | Confirms changes in signal are not due to expression differences |
| Peptide Competition | Pre-incubate antibody with immunizing peptide | Validates signal specificity |
| Secondary Antibody Control | Omit primary antibody | Checks for non-specific binding of secondary antibody |
These controls are particularly important given observed unspecific binding in immunoblotting experiments, as indicated by arrowheads in the research data showing antibody cross-reactivity .
YEL023C antibodies can be strategically deployed to study phosphorylation-dependent interactions through several sophisticated approaches:
Phosphorylation-state specific antibodies: Generate antibodies that specifically recognize phosphorylated or non-phosphorylated forms of Nbp2p to determine how phosphorylation affects its binding properties.
Combined immunoprecipitation and phosphoproteomic analysis: Use YEL023C antibodies to pull down Nbp2p complexes followed by phosphoproteomic analysis to identify phosphorylation sites on both Nbp2p and its binding partners.
Kinase inhibitor studies: Combine YEL023C antibody-based interaction assays with specific kinase inhibitors to determine which phosphorylation events regulate complex formation.
Mutation analysis: Compare antibody-based detection of wild-type versus phospho-site mutants of Nbp2p to determine the impact of specific residues on interaction stability.
These approaches can help unravel how Nbp2p integrates into signaling networks like those observed in the DNA damage checkpoint response pathways similar to those described in result , where phosphorylation cascades play critical regulatory roles .
The structural motifs within antibodies can significantly influence YEL023C binding specificity and functionality. Research on other antibody systems has demonstrated that specific recurring motifs can enhance binding to particular epitopes. For instance, studies of SARS-CoV-2 antibodies identified a YYDRxG motif encoded by IGHD3-22 in the CDR H3 region that facilitated targeting to a functionally conserved epitope .
When designing or selecting antibodies against YEL023C-encoded Nbp2p, researchers should consider:
CDR composition: The complementarity-determining regions, particularly CDR H3, significantly impact binding specificity
Framework regions: These can influence the orientation and stability of the binding pocket
Recurring motifs: Analysis of successful antibodies may reveal characteristic sequence patterns that enhance Nbp2p recognition
Isotype selection: Different antibody isotypes offer varying flexibility and avidity that can affect binding to different Nbp2p conformational states
Structural studies combining X-ray crystallography or cryo-EM with computational analysis can help identify optimal antibody structural features for YEL023C recognition .
Developing antibodies against different conformational states of the YEL023C-encoded protein presents several significant challenges:
Conformational dynamics: Nbp2p likely undergoes conformational changes when binding different partners through its SH3 domain and N-terminal region, making it difficult to capture specific interaction states.
Epitope accessibility: Key binding interfaces may be obscured in certain protein complexes, limiting antibody access to important epitopes.
Stability of conformational states: Isolating and maintaining Nbp2p in specific conformational states during immunization or screening is technically challenging.
Validation complexity: Confirming that antibodies recognize specific conformational states requires sophisticated biophysical techniques beyond standard validation methods.
Cross-reactivity concerns: Antibodies developed against one conformational state may cross-react with similar structural features in other proteins.
To address these challenges, researchers might employ strategies such as using constrained peptides that mimic specific structural elements, developing nanobody or single-domain antibody alternatives, or employing conformation-locking mutations during antigen preparation .
When encountering conflicting data about YEL023C/Nbp2p interactions, researchers should implement a systematic interpretation approach:
Common sources of false results when using YEL023C antibodies include:
| Error Type | Potential Causes | Prevention Strategies |
|---|---|---|
| False Positives | Cross-reactivity with related SH3 domain proteins | Pre-absorb antibodies against related proteins |
| Non-specific binding to highly abundant proteins | Include appropriate blocking agents | |
| Secondary antibody cross-reactivity | Include secondary-only controls | |
| False Negatives | Epitope masking in protein complexes | Use multiple antibodies targeting different regions |
| Low expression of target protein | Optimize extraction methods; concentrate samples | |
| Denaturation of conformational epitopes | Use native conditions when possible | |
| Post-translational modifications affecting epitope | Generate modification-insensitive antibodies |
The research specifically notes instances of non-specific binding in immunoblotting experiments, indicating this is a common challenge when working with these antibodies .
Optimizing antibody-based assays for YEL023C under challenging experimental conditions requires strategic adaptations:
For low abundance detection: Implement signal amplification systems such as tyramide signal amplification or polymer-based detection systems. Consider using antibody fragments for better tissue penetration in immunohistochemistry applications.
For detection in complex mixtures: Employ pre-clearing steps using control antibodies or protein A/G to remove non-specific binding proteins before immunoprecipitation, similar to approaches used in the GST-Nbp2p binding assays where specific elution conditions were optimized .
For variable expression conditions: Normalize results using housekeeping proteins and quantitative analysis, as demonstrated in experiments comparing Nub-Ptc1p expression levels across different strain backgrounds .
For detection of transient interactions: Consider chemical crosslinking approaches before immunoprecipitation to stabilize short-lived protein complexes, particularly relevant for Nbp2p's proposed role as an adaptor protein in dynamic signaling pathways.
For specificity enhancement: Develop sandwich-style detection using pairs of antibodies recognizing different Nbp2p epitopes, reducing false positives in complex samples .
Antibodies against YEL023C-encoded Nbp2p could significantly advance our understanding of DNA damage response pathways through several innovative applications:
Tracking Nbp2p relocalization during DNA damage: Similar to the telophase-specific responses observed in DNA double-strand break studies, Nbp2p may undergo specific subcellular relocalization during damage response that could be mapped using immunofluorescence with anti-Nbp2p antibodies .
Identifying damage-induced interaction partners: Immunoprecipitation using anti-Nbp2p antibodies before and after DNA damage induction could reveal condition-specific binding partners, potentially connecting Nbp2p to checkpoint kinase networks similar to the Rad53-dependent pathways observed in telophase cells .
Analyzing post-translational modifications: Phospho-specific antibodies against Nbp2p could determine if it undergoes modification in response to DNA damage, similar to the hyperphosphorylation of Rad53 observed during checkpoint activation .
Monitoring adaptor protein dynamics: Given Nbp2p's role as an adaptor protein, antibodies could track how it mediates phosphatase targeting during recovery from DNA damage checkpoints, potentially connecting it to cell cycle progression mechanisms .
These approaches could place Nbp2p within the broader context of stress response networks that coordinate cellular adaptation to genomic damage .
Several innovative methodological approaches are emerging for studying low-abundance YEL023C interactions:
Proximity labeling techniques: Methods like BioID or APEX2 fused to Nbp2p could identify transient or weak interactors through biotinylation of proximal proteins, enabling detection of interactions that might be missed in traditional pull-down assays.
Single-molecule imaging: Using fluorescently labeled antibodies against Nbp2p for super-resolution microscopy could reveal spatial organization of low-abundance complexes in situ.
Mass spectrometry enhancement: Combining immunoprecipitation with advanced MS techniques like Selected Reaction Monitoring (SRM) or Parallel Reaction Monitoring (PRM) can detect low-abundance interactors with greater sensitivity than conventional approaches.
Split fluorescent protein complementation: Similar to the Split-Ub system used in the research, but with fluorescent readouts for live-cell visualization of interactions and their dynamics .
Nanobody-based detection: Developing nanobodies against Nbp2p could offer advantages in terms of epitope accessibility and penetration into complex structures.
These approaches could overcome the limitations noted in conventional assays where certain interactions, like those between Nbp2p and Ste20p/Cla4p, were not detected in particular configurations .